Recombinant human bone morphogenetic protein 6
重组人骨形态发生蛋白6
Report date: 2024/02/28 13:36:28
Base Information
Drug NameRecombinant human bone morphogenetic protein 6
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAngitia Biopharmaceuticals (Guangzhou) Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesAngitia Biopharmaceuticals (Guangzhou) Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A